A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Treating high-risk Covid-19 patients with the antidepressant fluvoxamine may reduce the risk of prolonged hospitalisation by up to a third, a large-scale study showed Thursday.
An inexpensive antidepressant used to treat obsessive-compulsive disorder, also helps lower the likelihood of high-risk COVID-19 patients requiring hospitalization or prolonged medical observation, a large clinical trial published in The Lancet sugge
By Maggie Fox, CNN A cheap, generically available anti-depressant may reduce the risk of severe Covid-19 disease by close to a third in people at high risk, researchers reported Wednesday. A trial among about 1,500 patients in Brazil showed those who took the drug, known as fluvoxamine, were less li…
Trial in Brazil finds 11% of high-risk patients on fluvoxamine needed hospitalization, compared with 16% who were given the placebo; course of the treatment costs just $4
An affordable antidepressant has been found in a clinical trial to reduce the risk of hospitalization in high-risk adults with recently diagnosed COVID-19, according to a study
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
$4 antidepressant shows promise against early COVID-19 symptoms; more study needed | Since Then
